Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 Black Phoenix Black Phoenix +26.23%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.62%
#4 Fake World Assets Fake World Assets +15.66%
#5 OpenEden OpenEden +13.12%
#6 clBTC clBTC +12.10%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.63%
#8 Pons Pons +10.75%
#9 Akedo Akedo +9.52%
#10 TENDIES TENDIES +9.06%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Nabriva Therapeutics plc Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRV
Clasificación en acciones #39979
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Precio por acción
$0.63
Última sincronización: 2023-08-29
Capitalización bursátil
$284.20K
Cambio (1 día)
-21.25%
Cambio (1 año)
0.00%
País
IE
Comercio Nabriva Therapeutics plc (NBRV)

Categoría

Healthcare
Historial del precio de la acción de Nabriva Therapeutics plc (NBRV)
Precio más alto de cierre: $0.72 el 2023-08-01

Precio más bajo de cierre: $2.65K el 2015-09-01
Historial del precio de la acción de Nabriva Therapeutics plc desde 2015 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2023 -62.69%
2022 -88.16%
2021 -77.92%
2020 -82.12%
2019 -3.21%
2018 -70.79%
2017 19.90%
2016 -48.03%
2015 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $517.18 32.51%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $857.76 31.47%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $744.96 9.07%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.27%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $259.89 14.81%
BE